Cargando…

Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up

Calcineurin inhibitor (CNI) toxicity contributes to chronic allograft nephropathy (CAN). In the 2-year, randomized, study, we showed that 50% cyclosporin (CsA) reduction in combination with mycophenolate mofetil (MMF) treatment improves kidney function without increasing the risk for graft rejection...

Descripción completa

Detalles Bibliográficos
Autores principales: Frimat, L., Cassuto-Viguier, E., Provôt, F., Rostaing, L., Charpentier, B., Akposso, K., Moal, M. C., Lang, P., Glotz, D., Caillard, S., Ducloux, D., Pouteil-Noble, C., Girardot-Seguin, S., Kessler, M.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913628/
https://www.ncbi.nlm.nih.gov/pubmed/20706667
http://dx.doi.org/10.1155/2010/402750
_version_ 1782184681692725248
author Frimat, L.
Cassuto-Viguier, E.
Provôt, F.
Rostaing, L.
Charpentier, B.
Akposso, K.
Moal, M. C.
Lang, P.
Glotz, D.
Caillard, S.
Ducloux, D.
Pouteil-Noble, C.
Girardot-Seguin, S.
Kessler, M.
author_facet Frimat, L.
Cassuto-Viguier, E.
Provôt, F.
Rostaing, L.
Charpentier, B.
Akposso, K.
Moal, M. C.
Lang, P.
Glotz, D.
Caillard, S.
Ducloux, D.
Pouteil-Noble, C.
Girardot-Seguin, S.
Kessler, M.
author_sort Frimat, L.
collection PubMed
description Calcineurin inhibitor (CNI) toxicity contributes to chronic allograft nephropathy (CAN). In the 2-year, randomized, study, we showed that 50% cyclosporin (CsA) reduction in combination with mycophenolate mofetil (MMF) treatment improves kidney function without increasing the risk for graft rejection/loss. To investigate the long-term effect of this regimen, we conducted a follow up study in 70 kidney transplant patients until 5 years after REFERENCE initiation. The improvement of kidney function was confirmed in the MMF group but not in the control group (CsA group). Four graft losses occurred, 2 in each group (graft survival in the MMF group 95.8% and 90.9% in control group). One death occurred in the control group. There was no statistically significant difference in the occurrence of serious adverse events or acute graft rejections. A limitation is the weak proportion of patient still remaining within the control group. On the other hand, REFERENCE focuses on the CsA regimen while opinions about the tacrolimus ones are still debated. In conclusion, CsA reduction in the presence of MMF treatment seems to maintain kidney function and is well tolerated in the long term.
format Text
id pubmed-2913628
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-29136282010-08-12 Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up Frimat, L. Cassuto-Viguier, E. Provôt, F. Rostaing, L. Charpentier, B. Akposso, K. Moal, M. C. Lang, P. Glotz, D. Caillard, S. Ducloux, D. Pouteil-Noble, C. Girardot-Seguin, S. Kessler, M. J Transplant Clinical Study Calcineurin inhibitor (CNI) toxicity contributes to chronic allograft nephropathy (CAN). In the 2-year, randomized, study, we showed that 50% cyclosporin (CsA) reduction in combination with mycophenolate mofetil (MMF) treatment improves kidney function without increasing the risk for graft rejection/loss. To investigate the long-term effect of this regimen, we conducted a follow up study in 70 kidney transplant patients until 5 years after REFERENCE initiation. The improvement of kidney function was confirmed in the MMF group but not in the control group (CsA group). Four graft losses occurred, 2 in each group (graft survival in the MMF group 95.8% and 90.9% in control group). One death occurred in the control group. There was no statistically significant difference in the occurrence of serious adverse events or acute graft rejections. A limitation is the weak proportion of patient still remaining within the control group. On the other hand, REFERENCE focuses on the CsA regimen while opinions about the tacrolimus ones are still debated. In conclusion, CsA reduction in the presence of MMF treatment seems to maintain kidney function and is well tolerated in the long term. Hindawi Publishing Corporation 2010 2010-07-28 /pmc/articles/PMC2913628/ /pubmed/20706667 http://dx.doi.org/10.1155/2010/402750 Text en Copyright © 2010 L. Frimat et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Frimat, L.
Cassuto-Viguier, E.
Provôt, F.
Rostaing, L.
Charpentier, B.
Akposso, K.
Moal, M. C.
Lang, P.
Glotz, D.
Caillard, S.
Ducloux, D.
Pouteil-Noble, C.
Girardot-Seguin, S.
Kessler, M.
Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
title Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
title_full Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
title_fullStr Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
title_full_unstemmed Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
title_short Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
title_sort long-term impact of cyclosporin reduction with mmf treatment in chronic allograft dysfunction: referenece study 3-year follow up
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913628/
https://www.ncbi.nlm.nih.gov/pubmed/20706667
http://dx.doi.org/10.1155/2010/402750
work_keys_str_mv AT frimatl longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT cassutoviguiere longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT provotf longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT rostaingl longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT charpentierb longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT akpossok longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT moalmc longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT langp longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT glotzd longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT caillards longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT duclouxd longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT pouteilnoblec longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT girardotseguins longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup
AT kesslerm longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup